Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Blast Crisis
Bone Marrow
Cladribine
Cytarabine
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Granulocyte Colony-Stimulating Factor
Humans
Imatinib Mesylate
Leukemia, Myeloid, Acute
Male
Middle Aged
Piperazines
Pyrimidines
Recurrence
Time Factors

authors with profiles

Michael A. Becker